Yazar "Bilgic, Celal Ismail" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Docetaxel-induced Scleroderma in A Breast Cancer Patient: A Case Report
    (Aves, 2015) Kilic, Murat Ozgur; Yalaza, Metin; Bilgic, Celal Ismail; Dener, Cenap
    Paclitaxel and docetaxel are antineoplastic drugs derived from the yew tree, Taxus brevifolia. They are the members of the taxane family and act by inhibiting mitotic activity due to the suppression of microtubule depolymerization. They are used in the treatment of ovarian cancer, breast cancer, gastric cancer, small cell lung cancer, and head and neck cancer. In addition to side effects such as cardiotoxicity, neutropenia, arthralgia, and myalgia, they may also cause alopecia, urticaria, mucositis, acral erythema, pustular dermatitis, erythema multiforme, and scleroderma-like mucocutaneous lesions. Scleroderma is among the uncommon side effects of taxane antineoplastic agents. As was the case in few cases in literature, it usually begins with edematous changes in the proximal aspect of the extremities, and subsequently, sclerosis is developed in the skin. Scleroderma, which usually regresses with the discontinuation of the drug and with steroid therapy, may lead to severe contractions that require physical therapy and rehabilitation in some patients. In this paper, we presented a 60-year-old female patient in whom scleroderma developed because docetaxel chemotherapy for breast cancer because it is encountered rarely.
  • Küçük Resim Yok
    Öğe
    The Clinicopathological Factors Associated with Multicentricity in Papillary Thyroid Cancer
    (Derman Medical Publ, 2016) Kilic, Murat Ozgur; Bilgic, Celal Ismail; Dener, Cenap; Icen, Duygu
    Aim: Multicentricity is a frequent feature of papillary thyroid cancer, and is generally associated with advanced stage, increased risk of regional and distant metastasis. In this study, we aimed to determine the associated clinicopathological factors on multicentricity in papillary thyroid cancer. Material and Method: One hundred and thirty patients with papillary thyroid cancer were included in this retrospective study. The affecting clinical and histopathological factors on multicentricity were investigated. Results: Total thyroidectomy with or without central/lateral neck dissection was performed in 130 patients (101, 77.7% were female and 29, 22.3% were male) with a mean age of 43.03 years. The diagnosis of papillary thyroid cancer was confirmed by final histopathology in all cases. Multicentricity and bilaterality were detected in 54 (41.5%) and 16 (12.3%) patients, respectively. Tumor size (p= 0.046) and perineural invasion (p= 0.020) were significantly different between the patients with multicentric cancer and those with solitary cancer. Discussion: According to the findings obtained from this study, tumor size and perineural invasion were the affecting factors on multicentricity in papillary thyroid cancer. However, large-scale, multicenter clinical and genetic studies are needed to clearly determine the affecting factors on multicentricity of these cancers.
  • Küçük Resim Yok
    Öğe
    The effect of survivin gene promoter polymorphism on breast cancer
    (Tubitak Scientific & Technological Research Council Turkey, 2014) Altiparmak, Mehmet Deniz; Bilgic, Celal Ismail; Dener, Nuzhet Cenap; Gunduz, Esra; Yenidunya, Sibel; Acar, Muradiye; Sen, Meral
    Breast cancer is the most common malignant tumor in women and accounts for about 25% of all cancer diagnoses. Survivin is a member of the apoptosis inhibitor protein family of antiapoptotic proteins. In our study, we investigated one of those, the survivin gene promoter 31G/C polymorphism. Included in this study were 111 breast cancer patients who were operated on in our hospital and 101 healthy female subjects. Blood samples from the healthy subjects and paraffin-embedded tissue samples from the patients were used for DNA extraction and subsequent genetic analysis. PCR-RFLP was used for genotype analysis. We established the clinicopathologic characteristics of patients. No significant difference was found between survivin 31G/C promoter polymorphism of tumor characteristics and breast cancer. Between the control and breast cancer groups, survivin promoter polymorphism 31G/C differences were not significantly different (P = 0.058). The risk of developing cancer, having the relevant GC or CC genotype, is 1.413 times higher than those having genotype GG (95% confidence interval: 1.040 to 1.918). Carrying the C allele was statistically significant in terms of susceptibility to breast cancer. In conclusion, the use of survivin gene polymorphism as a risk factor in breast cancer is recommended based on the results of this study.